Ameriprise
SPRY icon

Ameriprise’s ARS Pharmaceuticals SPRY Stock Holding History

Ameriprise’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-345,055
Closed -$6.02M – 4178
2025
Q2 		$6.02M Buy
345,055
+240,945
+231% +$3.48M ﹤0.01% 2223
2025
Q1 		$1.31M Buy
104,110
+34,734
+50% +$418K ﹤0.01% 3096
2024
Q4 		$732K Buy
69,376
+36,928
+114% +$517K ﹤0.01% 3380
2024
Q3 		$470K Buy
+32,448
New +$386K ﹤0.01% 3503
2024
Q2 		– Sell
-34,570
Closed -$353K – 3936
2024
Q1 		$353K Sell
34,570
-41,720
-55% -$311K ﹤0.01% 3537
2023
Q4 		$418K Sell
76,290
-78,221
-51% -$343K ﹤0.01% 3515
2023
Q3 		$584K Sell
154,511
-121,675
-44% -$799K ﹤0.01% 3349
2023
Q2 		$1.85M Sell
276,186
-4,143
-1% -$27.7K ﹤0.01% 2915
2023
Q1 		$1.82M Buy
280,329
+244,919
+692% +$1.88M ﹤0.01% 2889
2022
Q4 		$302K Sell
35,410
-1,885
-5% -$12.2K ﹤0.01% 3583
2022
Q3 		$197K Buy
+37,295
New +$184K ﹤0.01% 3713
2021
Q3 		– Sell
-448,294
Closed -$13.8M – 3951
2021
Q2 		$13.8M Buy
448,294
+22,797
+5% +$731K ﹤0.01% 1650
2021
Q1 		$18.6M Sell
425,497
-3,217
-0.8% -$152K 0.01% 1376
2020
Q4 		$19.8M Buy
+428,714
New +$14.3M 0.01% 1233

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Ameriprise's SPRY Position: Q3 2025 in Review

Ameriprise sold out of ARS Pharmaceuticals (SPRY) in Q3 2025, closing a stake of 345,055 shares — an estimated $6.02M sold.

Ameriprise first reported a position in SPRY in Q4 2020 and held it in 14 quarters. The position peaked at $19.8M in Q4 2020. 188 funds tracked by Wall St. Rank hold SPRY as of Q3 2025.

  • Ameriprise reported no remaining ARS Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Ameriprise sold 345,055 ARS Pharmaceuticals shares in Q3 2025, an estimated $6.02M.
  • Ameriprise first reported a position in ARS Pharmaceuticals in Q4 2020 and held it in 14 quarters.
  • Ameriprise's ARS Pharmaceuticals position peaked at $19.8M in Q4 2020.
  • 188 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2025.

Based on Ameriprise's 13F filing for Q3 2025, filed 14 Nov 2025.